Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Phase 2 Recruiting 47 enrolled Sun Yat-sen University

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype

Timeline

Start: 2022-09-01
Primary completion: 2024-09-01
Completion: 2026-09-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tucidinostat	Small molecule	20 mg	Oral
Background	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Background	Doxorubicin	Other / unclassified	50 mg/m2	Intravenous
Background	Epirubicin	Small molecule	70 mg/m2	Intravenous
Background	Prednisone	Other / unclassified	40 mg/m2	Oral
Background	Vincristine	Small molecule	1.4 mg/m2	Intravenous

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Summary

Timeline

Drugs

Indications